Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus surface antigen (envelope of HDV particle) (HBsAg; sometimes referred to as HDV envelope (not standardized))
- Target
- HBsAg; sometimes referred to as HDV envelope (not standardized)
- Molecular classification
- Viral envelope protein (source: HBV), Subviral particle component, Glycoprotein
01
Overview
The **envelope layer of the hepatitis D virus particle** is made entirely from the hepatitis B virus surface proteins (HBsAg: S, M, and L proteins) and a host-derived lipid bilayer[2][3][8][9]. HDV, a unique subviral agent, relies on HBV as a helper virus; it packages its ribonucleoprotein complex (HDV genome plus delta antigen) inside an envelope composed of HBV surface antigens. This envelope is necessary for HDV infectivity, mediating attachment to hepatocytes and entry via the sodium taurocholate cotransporting polypeptide (NTCP) receptor[6][7]. HDV envelope proteins are not products of HDV itself but are fully sourced from HBV within coinfected cells[2][8].
- Other names
- HBV surface antigenHBsAgEnvelope of HDV virionHDV envelope (used in some literature, not strictly correct)
02
Mechanism of action
Bulevirtide: inhibits interaction of viral envelope (preS1 domain of HBsAg-L) with NTCP receptor, preventing viral entry
03
Biological functions
Virion assembly and releaseMediation of viral entry via binding to NTCP receptor on hepatocytesDeterminant of infectivity and host cell tropism
04
Disease associations
Infection (essential for HDV infectivity)Progression to severe liver disease, including cirrhosis and hepatocellular carcinoma (conferred by HDV/HBV coinfection)
05
Safety considerations
Reliance on HBV surface antigen for HDV eradication: inhibition may affect HBV infection, risk for liver enzyme flares or hepatitis rebound upon withdrawaloff-target immune effects, interferon-related adverse reactions
06
Interacting drugs
Bulevirtide (blocks entry of HDV and HBV by targeting the NTCP receptor)
1 more in the full profile.
07
Biomarkers
HBsAg (used as marker for HBV infection and required for HDV presence)HDV RNA (confirms HDV infection, not envelope-specific)
Beyond the preview
Go deeper on Hepatitis B virus surface antigen (envelope of HDV particle) (HBsAg; sometimes referred to as HDV envelope (not standardized)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatitis B virus surface antigen (envelope of HDV particle) (HBsAg; sometimes referred to as HDV envelope (not standardized)).